TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Sees Large Growth in Short Interest

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 172,000 shares, a growth of 20.5% from the October 15th total of 142,700 shares. Based on an average daily volume of 71,600 shares, the short-interest ratio is presently 2.4 days. Currently, 5.6% of the shares of the company are short sold.

TFF Pharmaceuticals Trading Down 76.5 %

Shares of NASDAQ:TFFP traded down $1.22 on Friday, reaching $0.38. 9,167,990 shares of the company’s stock were exchanged, compared to its average volume of 94,204. TFF Pharmaceuticals has a twelve month low of $0.27 and a twelve month high of $11.00. The company has a fifty day moving average of $2.02 and a 200-day moving average of $1.99. The company has a market capitalization of $1.31 million, a price-to-earnings ratio of -0.05 and a beta of 1.32.

TFF Pharmaceuticals (NASDAQ:TFFP) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.70) by $0.48. The firm had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.15 million. TFF Pharmaceuticals had a negative return on equity of 225.15% and a negative net margin of 1,612.73%. As a group, equities research analysts forecast that TFF Pharmaceuticals will post -4.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TFF Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 185,695 shares of the company’s stock, valued at approximately $308,000. Armistice Capital LLC owned approximately 5.99% of TFF Pharmaceuticals as of its most recent SEC filing. 15.25% of the stock is currently owned by hedge funds and other institutional investors.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.